ID   DS
AC   CVCL_QX99
DR   ATCC; CRL-3381
DR   Cosmic; 1086333
DR   Wikidata; Q54831425
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8035608;
RX   PubMed=8558920;
RX   PubMed=20664054;
RX   PubMed=20889926;
RX   PubMed=26727417;
RX   PubMed=29416618;
RX   PubMed=29666304;
CC   Population: Caucasian.
CC   Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC=CRL-3381
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 13
ST   D16S539: 11,13
ST   D5S818: 11,12
ST   D7S820: 11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C36080; Diffuse large B-cell lymphoma germinal center B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 02-05-24; Version: 9
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=8035608;
RA   Lambrechts A.C., Dorssers L.C.J., Hupkes P.E., van Gurp R.J.H.L.M.,
RA   Baumgarten R., Hagemeijer A., van 't Veer M.B., Touw I.P.;
RT   "Genomic organization of the translocations (8;14) and (14;18) in a
RT   new lymphoma cell line.";
RL   Leukemia 8:1164-1171(1994).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=20664054; DOI=10.1182/blood-2009-12-257378; PMCID=PMC2981542;
RA   Pham L.V., Tamayo A.T., Li C.-P., Bueso-Ramos C.E., Ford R.J. Jr.;
RT   "An epigenetic chromatin remodeling role for NFATc1 in transcriptional
RT   regulation of growth and survival genes in diffuse large B-cell
RT   lymphomas.";
RL   Blood 116:3899-3906(2010).
//
RX   PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744;
RA   Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E.,
RA   Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.;
RT   "Constitutive BR3 receptor signaling in diffuse, large B-cell
RT   lymphomas stabilizes nuclear factor-kappaB-inducing kinase while
RT   activating both canonical and alternative nuclear factor-kappaB
RT   pathways.";
RL   Blood 117:200-210(2011).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//